Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?

dc.creatorNóbrega, Ana Caline
dc.creatorRodrigues, Bernardo
dc.creatorTorres, Ana Catarina Moura
dc.creatorEnzo, Alfredo
dc.creatorMelo, Ailton de Souza
dc.creatorNóbrega, Ana Caline
dc.creatorRodrigues, Bernardo
dc.creatorTorres, Ana Catarina Moura
dc.creatorEnzo, Alfredo
dc.creatorMelo, Ailton de Souza
dc.date.accessioned2022-10-07T19:13:43Z
dc.date.available2022-10-07T19:13:43Z
dc.date.issued2007
dc.identifier0022-510X
dc.identifierhttp://repositorio.ufba.br/ri/handle/ri/15981
dc.identifierv. 253, n. 1-2
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4013196
dc.description.abstractThis study analysed if botulinum toxin type A (BTX-A) decreases drooling in 21 Parkinson's disease patients. BTX-A injections were given in the parotid glands. The severity of drooling decreased in 18 (86%) patients, while frequency was reduced in 8 (38%). In 11(52%) patients, the frequency of drooling remained constant, which may reflect more difficulties in swallowing, compared to the group that presented such improvement. Future trials assessing the level of swallowing dysfunction may be important to establish a prognosis for patients who keep the frequency of drooling in spite of decreased severity after BTX injection.
dc.languageen
dc.rightsAcesso Aberto
dc.sourcehttp://dx.doi.org/10.1016/j.jns.2006.11.015
dc.subjectDrooling
dc.subjectSialorrhea
dc.subjectParkinson's disease
dc.subjectBotulinum toxin
dc.titleDoes botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
dc.typeArtigo de Periódico


Este ítem pertenece a la siguiente institución